In the News

An interview with ICON’s Nuala Murphy, President, Clinical Research Services, on ‘How to run a coronavirus vaccine trial in a global pandemic.’ Dr. Murphy discusses ICON’s experience with the Pfizer/BioNTech COVID-19 vaccine, the world’s first COVID-19 vaccine to achieve Emergency Use Authorisation.

A thought leadership piece which examines how disruptions from COVID-19 have forced sponsors, clinicians and regulators to embrace digital's full potential to keep clinical trials moving forward.

ICON CEO Steve Cutler discusses how the Pfizer COVID vaccine trial proves that starting clinical trials in weeks, as opposed to months, should be possible post- pandemic.

Marie McCarthy and Manpreet Sidhu discuss some of the challenges associated with the widespread adoption of digital health technology, the data that can be leveraged from wearables, and where advances are being made.

ICON recently contributed to the Irish Times' Life Sciences special feature with expert commentary from Dr. Nuala Murphy, President of Clinical Research Services, a case study with CFO Brendan Brennan, and a report on career opportunities for clinical researchers with a job profile of Rory Considine, Clinical Operations Manager.

In this Pharmafile article, Dr. Caroline Forkin and Shelley McLendon discuss a new decade of research and innovation on the horizon for HIV.

ICON’s Dr. Andrew Garrett, Executive Vice President Scientific Operations, comments on MHRA, the UK regulator, following their emergency use authorisation of the Pfizer COVID-19 vaccine.

An interview with EB McLindon on why the future of drug development involves decentralising parts of the clinical trial process.

This article reports on ICON's new whitepaper "The evolution of HIV treatments: From PrEP to vaccines, where we are today and what’s next".

Pharmafocus features a thought leadership piece by Rose Kidd which examines the benefits of agile clinical monitoring in study management.